The Globe and Mail reports in its Saturday, May 16, edition that Desjardins Securities analyst John Chu raised Aurora Cannabis ($15.35) to "buy" from "hold." The Globe's David Leeder writes that Mr. Chu boosted his share target to $19 from $3.25. Analysts on average target the shares at $18.15. Mr. Chu says the company is "pulling out all the stops to get to positive EBITDA." He says in a note: "Regardless of how sales may materialize in this post-COVID-19 environment, [Aurora] is ready to pull as many cost-related levers ('cost reductions and efficiencies in COGS and SG&A, if necessary.') toward its goal of reaching positive EBITDA by 1Q (recall, this is also one of the covenants imposed by its lenders, hence the urgency). Thus, with the progress on the operating cost savings thus far and given its current run rate ($50-million in 4Q), we believe the company will cut to the bone if necessary to generate modestly positive EBITDA in 1Q FY20 (ending September). How deep it needs to cut and the impact it could have on driving future sales growth remains to be seen. ... We have reduced our EBITDA outlook as our more conservative gross margin outlook more than offsets our assumption of lower operating expenses."